<DOC>
	<DOCNO>NCT01529541</DOCNO>
	<brief_summary>This trial evaluate efficacy safety CWP-0403 compare Sitagliptin prove non-inferiority patient type 2 Diabetes Mellitus insufficiently control metformin alone .</brief_summary>
	<brief_title>Efficacy Safety CWP-0403 Compared Sitagliptin Patients With Type 2 Diabetes Mellitus Insufficiently Controlled With Metformin Alone</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Sitagliptin Phosphate</mesh_term>
	<criteria>Patients diagnose type 2 DM 3 month Men woman age ≥ 19 ≤ 75 year FPG ≤ 270 mg/dL screen visit Patients consent participate trial write Informed Consent Form Type 1 DM secondary diabetes Subjects administrate oral antihyperglycemic drug take medicine Body mass index &lt; 20 kg/m2 &gt; 40.0kg/m2 Subjects assessed inappropriate trial investigator</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>CWP-0403</keyword>
	<keyword>Sitagliptin</keyword>
	<keyword>Metformin</keyword>
	<keyword>type 2 DM</keyword>
</DOC>